Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
gp100 Peptide Vaccine + High Dose IL-2 vs High Dose IL-2 Alone in Metastatic Melanoma
NCT00019682Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 1999
- Primary completion
- May 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of gp100 antigen in melanoma, sponsored by National Cancer Institute. Started Dec 1999; status: completed.
02
Drugs
gp100 antigen
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00019682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019682.